13F filer · CIK 1352851 ↗
Magnetar Financial LLC
You are looking at Q3 2020. See the latest, Q2 2026 →
Reported value
$5.66B
+67% on the quarter before
Positions
640
380 new · 158 sold out
Top 10
26.9%
of the value
Est. gain
+$102.3M
on stocks held all quarter
Est. return
+4.3%
on those stocks since Q2 2020
Positions as of Sep 30, 2020, from Magnetar Financial LLC's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
The 24 largest positions, 45% of the reported value, each sized by its share, colored by what the fund did with it since Q2 2020. Striped tiles are options.
Largest buys
Since Q2 2020, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Churchill Capital Corp Iv~$180.2MNew · 0.0% → 3.2%+17,982,000 shares
- Varian Med Sys Inc~$164.0MNew · 0.0% → 2.9%+953,718 shares
- Maxim Integrated Prods Inc~$160.9MNew · 0.0% → 2.8%+2,379,192 shares
- Livongo Health Inc~$157.0MNew · 0.0% → 2.8%+1,121,264 shares
- Churchill Cap Corp Iii~$112.6MNew · 0.0% → 2.0%+10,989,997 shares
- Momenta Pharmaceuticals Inc~$102.1MNew · 0.0% → 1.8%+1,946,428 shares
- Immunomedics Inc~$89.5MNew · 0.0% → 1.6%+1,052,070 shares
- Bmc Stk Hldgs Inc~$85.0MNew · 0.0% → 1.5%+1,984,305 shares
- Ftac Olympus Acquisition Cor~$72.0MNew · 0.0% → 1.3%+7,200,000 shares
- Aimmune Therapeutics Inc~$66.3MNew · 0.0% → 1.2%+1,925,576 shares
Largest sells
Since Q2 2020, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Churchill Cap Corp Iii~$124.1MSold out · 3.7% → 0.0%−10,970,688 shares
- Qiagen Nv~$96.8MSold out · 2.9% → 0.0%−2,247,635 shares
- Caesars Entmt Corp~$84.0MSold out · 2.5% → 0.0%−6,928,957 shares
- Portola Pharmaceuticals Inc~$72.3MSold out · 2.1% → 0.0%−4,017,446 shares
- Uber~$37.0MCut · 1.3% → 0.3%−1,014,999 shares
- Sunnova Energy Intl Inc.~$35.9MCut · 1.1% → 0.6%−1,178,925 shares
- Graf Indl Corp~$35.1MSold out · 1.0% → 0.0%−2,525,000 shares
- Fintech Acquisition Corp Iii~$30.1MSold out · 0.9% → 0.0%−2,700,000 shares
- Terraform Pwr Inc~$22.1MSold out · 0.7% → 0.0%−1,198,199 shares
- Fortress Value Acquisition C~$21.1MSold out · 0.6% → 0.0%−2,049,499 shares
Holdings
As of Sep 30, 2020. Changes are in shares against Jun 30, 2020, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Willis Towers Watson Plc LtdSHS · shares −4.1% · price +6.0% | 3.7% | $207.5M | +$11.8M | ||||||||
| Churchill Capital Corp IvUNIT 99/99/9999 ADDED · shares New | 3.2% | $180.2M | — | ||||||||
| Varian Med Sys IncCOM · shares New | 2.9% | $164.0M | — | ||||||||
| Maxim Integrated Prods IncCOM · shares New | 2.8% | $160.9M | — | ||||||||
| Livongo Health IncCOM · shares New | 2.8% | $157.0M | — | ||||||||
| E Trade Financial CorpCOM NEW · shares −3.9% · price +0.6% | 2.6% | $146.4M | +$936,050 | ||||||||
| Wright Med Group N VORD SHS · shares +1.9% · price +2.8% | 2.5% | $140.7M | +$3.7M | ||||||||
| Td Ameritrade Hldg CorpCOM · shares −2.1% · price +7.6% | 2.4% | $134.8M | +$9.5M | ||||||||
| Acacia Communications IncCOM · shares +1.5% · price +0.3% | 2.1% | $117.9M | +$361,039 | ||||||||
| Churchill Cap Corp IiiCOM · shares New | 2.0% | $112.6M | — | ||||||||
| Momenta Pharmaceuticals IncCOM · shares New | 1.8% | $102.1M | — | ||||||||
| Immunomedics IncCOM · shares New | 1.6% | $89.5M | — | ||||||||
| Flying Eagle Acquisition CorUNIT 99/99/9999 · shares 0% · price +10.8% | 1.6% | $88.6M | +$8.6M | ||||||||
| Grubhub IncCOM · shares +19% · price +2.9% | 1.5% | $86.0M | +$2.0M | ||||||||
| Bmc Stk Hldgs IncCOM · shares New | 1.5% | $85.0M | — | ||||||||
| Advanced Disp Svcs Inc DelCOM · shares +1.8% · price +0.2% | 1.4% | $77.9M | +$151,636 | ||||||||
| Fitbit IncCL A · shares +1.7% · price +7.7% | 1.4% | $76.7M | +$5.4M | ||||||||
| Tiffany & Co NewCOM · shares +2.0% · price −5.0% | 1.3% | $74.0M | −$3.8M | ||||||||
| Ftac Olympus Acquisition CorUNIT 08/24/2025 ADDED · shares New | 1.3% | $72.0M | — | ||||||||
| Aimmune Therapeutics IncCOM · shares New | 1.2% | $66.3M | — | ||||||||
| Churchill Cap Corp IiUNIT 99/99/9999 · shares 0% · price −5.3% | 1.0% | $57.6M | −$3.3M | ||||||||
| Cf Finance Acquisition CorpUNIT 08/01/2027 ADDED · shares New | 0.88% | $49.6M | — | ||||||||
| Adc Therapeutics SaSHS · shares +3.8% · price −26.2% | 0.87% | $49.4M | −$16.9M | ||||||||
| Social Cap Hedspia Hldg Co IUNIT 99/99/9999 · shares 0% · price +16.2% | 0.83% | $47.0M | +$6.5M | ||||||||
| Foley Trasimene AcquisitionUNIT 99/99/9999 ADDED · shares New | 0.81% | $45.9M | — | ||||||||
| Total · 640 positions | 100% | $5.66B | +$102.3M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q2 2020 to Q3 2020: 251 stocks held throughout, up $102.3M (+4.3%).
- Sunnova Energy Intl Inc.+$13.7M+78%
- Willis Towers Watson Plc Ltd+$11.8M+6%
- Td Ameritrade Hldg Corp+$9.5M+8%
- Social Cap Hdosphia Hldg Co+$9.3M+67%
- Flying Eagle Acquisition Cor+$8.6M+11%
- Pae Inc−$1.3M−11%
- Perrigo Co Plc−$1.7M−17%
- Churchill Cap Corp Ii−$3.3M−5%
- Tiffany & Co New−$3.8M−5%
- Adc Therapeutics Sa−$16.9M−26%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $10.96B+11% | SEC ↗ |
| Q1 2026 | May 13, 2026 | $9.84B−4% | SEC ↗ |
| Q4 2025 | Feb 17, 2026 | $10.21B−38% | SEC ↗ |
| Q3 2025 | Nov 13, 2025 | $16.50B−20% | SEC ↗ |
| Q2 2025 | Aug 12, 2025 | $20.65B+171% | SEC ↗ |
| Q1 2025 | May 15, 2025 | $7.61B+75% | SEC ↗ |
| Q4 2024 | Feb 11, 2025 | $4.36B−6% | SEC ↗ |
| Q3 2024 | Nov 13, 2024 | $4.62B−4% | SEC ↗ |
| Q2 2024 | Aug 14, 2024 | $4.80B+7% | SEC ↗ |
| Q1 2024 | May 15, 2024 | $4.47B+13% | SEC ↗ |
| Q4 2023 | Feb 13, 2024 | $3.94B+1% | SEC ↗ |
| Q3 2023 | Nov 14, 2023 | $3.92B−14% | SEC ↗ |
| Q2 2023 | Aug 11, 2023 | $4.56B−11% | SEC ↗ |
| Q1 2023 | May 15, 2023 | $5.13B−13% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $5.91B−18% | SEC ↗ |
| Q3 2022 | Nov 14, 2022 | $7.21B−25% | SEC ↗ |
| Q2 2022 | Aug 15, 2022 | $9.67B+3% | SEC ↗ |
| Q1 2022 | May 16, 2022 | $9.37B−6% | SEC ↗ |
| Q4 2021 | Feb 14, 2022 | $9.96B+1% | SEC ↗ |
| Q3 2021 | Jan 14, 2022 (amended) | $9.82B−7% | SEC ↗ |
| Q2 2021 | Aug 6, 2021 | $10.56B+2% | SEC ↗ |
| Q1 2021 | May 14, 2021 | $10.40B+47% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $7.08B+25% | SEC ↗ |
| Q3 2020 | Nov 16, 2020 | $5.66B+67% | SEC ↗ |
| Q2 2020 | Aug 14, 2020 | $3.39B−18% | SEC ↗ |
| Q1 2020 | May 15, 2020 | $4.15B−13% | SEC ↗ |
| Q4 2019 | Feb 13, 2020 | $4.79B+22% | SEC ↗ |
| Q3 2019 | Nov 14, 2019 | $3.93B−21% | SEC ↗ |
| Q2 2019 | Aug 14, 2019 | $5.00B+29% | SEC ↗ |
| Q1 2019 | May 15, 2019 | $3.89B−5% | SEC ↗ |
| Q4 2018 | Feb 14, 2019 | $4.08B−26% | SEC ↗ |
| Q3 2018 | Feb 14, 2019 (amended) | $5.54B−16% | SEC ↗ |
| Q2 2018 | Aug 14, 2018 (amended) | $6.56B+13% | SEC ↗ |
| Q1 2018 | May 15, 2018 (amended) | $5.80B+3% | SEC ↗ |
| Q4 2017 | Feb 14, 2018 (amended) | $5.62B+2% | SEC ↗ |
| Q3 2017 | Nov 14, 2017 (amended) | $5.52B−15% | SEC ↗ |
| Q2 2017 | Aug 14, 2017 (amended) | $6.52B−7% | SEC ↗ |
| Q1 2017 | May 15, 2017 (amended) | $7.02B+1,897% | SEC ↗ |
| Q4 2016 | Aug 14, 2017 (amended) | $351.5M−95% | SEC ↗ |
| Q3 2016 | Nov 14, 2016 (amended) | $7.03B+17% | SEC ↗ |
| Q2 2016 | Aug 15, 2016 (amended) | $6.02B−7% | SEC ↗ |
| Q1 2016 | May 16, 2016 (amended) | $6.49B | SEC ↗ |